M. Amore, I. Favia, D. Amore, S. Scagliusi, P. Minenna et al., Asymptomatic hyper-creatinephosphokinasemia: a veritable disease? Observation in some cases, Recenti Prog Med, vol.1, 2005.

Z. Amoura, P. Duhaut, H. Du, and L. , Tumor Antigen Markers for the Detection of Solid Cancers in Inflammatory Myopathies, Cancer Epidemiology Biomarkers & Prevention, vol.14, issue.5, pp.1279-1282, 2005.
DOI : 10.1158/1055-9965.EPI-04-0624

K. Arahata and A. Engel, Monoclonal antibody analysis of mononuclear cells in myoptahies

U. Badrisin, M. Maat-schieman, and S. Van-duinen, Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis, Neurology, vol.63, issue.12, pp.2396-2404, 2004.
DOI : 10.1212/01.WNL.0000148588.15052.4C

U. Badrising, G. Schreuder, and M. Grpahart, Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis, Neurology, vol.63, issue.12, pp.2396-2398, 2004.
DOI : 10.1212/01.WNL.0000148588.15052.4C

B. Banker, Dermatomyositis of Childhood, Journal of Neuropathology & Experimental Neurology, vol.34, issue.1, pp.46-75, 1975.
DOI : 10.1097/00005072-197501000-00005

N. Basset-séguin, J. Roujeau, and R. Guerardi, Prognostic Factors and Predictive Signs of Malignancy in Adult Dermatomyositis, Archives of Dermatology, vol.126, issue.5, pp.633-637, 1990.
DOI : 10.1001/archderm.1990.01670290077012

M. Basta and M. Dalakas, High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments., Journal of Clinical Investigation, vol.94, issue.5, pp.1729-1735, 1994.
DOI : 10.1172/JCI117520

J. Benbassat, D. Geffel, K. Larholt, S. Sukenik, V. Morgenstern et al., Prognostic factors in polymyositis/dermatomyositis. A computer-assisted analysis of ninety-two cases, Arthritis & Rheumatism, vol.4, issue.3, pp.249-55, 1985.
DOI : 10.1002/art.1780280303

O. Benveniste, O. Dubourg, and S. Herson, Nouvelles classifications et??physiopathologie des??myopathies inflammatoires, La Revue de M??decine Interne, vol.28, issue.9, pp.603-612, 2007.
DOI : 10.1016/j.revmed.2007.03.004

O. Benveniste, Le muscle inflammatoire??: avanc??es en 2014, La Revue de M??decine Interne, vol.35, issue.7, pp.411-412, 2014.
DOI : 10.1016/j.revmed.2014.04.015

A. Bohan and J. Peter, Polymyositis and Dermatomyositis, New England Journal of Medicine, vol.292, issue.7, pp.344-351, 1975.
DOI : 10.1056/NEJM197502132920706

S. Bombardieri, G. Hughes, R. Neri, D. Bravo, P. et al., CYCLOPHOSPHAMIDE IN SEVERE POLYMYOSITIS, The Lancet, vol.333, issue.8647, pp.1138-1147, 1989.
DOI : 10.1016/S0140-6736(89)92416-1

M. Brandao and A. Marinho, Idiopathic inflammatory myopathies: Definition and management of refractory disease, Autoimmunity Reviews, vol.10, issue.11, pp.720-724, 2001.
DOI : 10.1016/j.autrev.2011.05.021

R. Buchbinder, A. Forbes, and S. Hall, Incidence of Malignant Disease in Biopsy-Proven Inflammatory Myopathy: A Population-Based Cohort Study, Annals of Internal Medicine, vol.134, issue.12, pp.1087-1095, 2001.
DOI : 10.7326/0003-4819-134-12-200106190-00008

T. Bunch, J. Worthington, J. Combs, D. Ilstrup, and A. Engel, Azathioprine with Prednisone for Polymyositis, Annals of Internal Medicine, vol.92, issue.3, pp.365-374, 1980.
DOI : 10.7326/0003-4819-92-3-365

T. Bunch, Prednisone and azathioprine for polymyositis. Long-term followup, Arthritis & Rheumatism, vol.1, issue.1, pp.45-53, 1981.
DOI : 10.1002/art.1780240107

P. Caramaschi, A. Volpe, A. Carlette, L. Bambara, and D. Biasi, Long-standing refractory polymyositis responding to mycophenolate mofetil: a case report and review of the literature, Clinical Rheumatology, vol.32, issue.Suppl 2, pp.1795-1801, 2007.
DOI : 10.1007/s10067-006-0526-5

R. Chakour, A. Leimgruber, P. Bart, and F. Spertini, Stratégies thérapeutiques dans les myopathies inflammatoires, Rev Med Suisse, vol.5, pp.812-818, 2009.

E. Chauvet, L. Sallier, S. Madaule, L. Astudillo, M. Delisle et al., Muscle diseases in an internal medicine department, Rev Med Interne, vol.6, pp.429-463, 2004.

Y. Chen, C. Wu, and J. Shen, Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study, British Journal of Dermatology, vol.14, issue.344, pp.825-831, 2001.
DOI : 10.1097/00000421-199602000-00008

P. Chérin, I. Auperin, A. Bussel, J. Pourrat, and S. Herson, Plasma exchange in polymyositis and dermatomyositis : a multicenter study of 57 cases, Clin Exp Rheumatol, vol.13, pp.270-271, 1995.

P. Cherin, S. Herson, B. Wechsler, O. Bletry, J. Piette et al., The reply, The American Journal of Medicine, vol.93, issue.1, pp.114-115, 1992.
DOI : 10.1016/0002-9343(92)90699-C

P. Chérin, P. Lafroret, R. Ghérardi, F. Authier, M. Coquet et al., Macrophagic myofasciitis, Current Rheumatology Reports, vol.121, issue.3, pp.483-492, 1999.
DOI : 10.1007/s11926-000-0079-6

P. Cherin, P. J. Wechsler, B. Bletry, O. , Z. J. Laraki et al., Intravenous gammaglobulin as first line therapy in polymyositis and dermatomyositis: a report of 11 cases, J

G. Chevrel, C. Granet, and P. Miossec, Contribution of tumour necrosis factor alpha and interleukin 1

H. Chinoy, N. Fertig, C. Oddis, W. Ollier, and R. Cooper, The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis, Annals of the Rheumatic Diseases, vol.66, issue.10, pp.1345-1354, 2007.
DOI : 10.1136/ard.2006.068502

M. Couderc, J. Gottenberg, X. Mariette, E. Hachulla, J. Sibilia et al., Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry, Rheumatology, vol.50, issue.12, pp.2283-2292, 2011.
DOI : 10.1093/rheumatology/ker305

N. Cox, C. Lawrence, and L. Langtry, Dermatomyositis. Disease associations and an evaluation of screening investigations for malignancy, Archives of Dermatology, vol.126, issue.1, pp.61-65, 1990.
DOI : 10.1001/archderm.126.1.61

M. Cronin, F. Miller, J. Hicks, M. Dalakas, and P. Plotz, The failure of intravenous cyclophosphamide therapy in refractory idioptathic inflammatory myopathy, J Rheumatol, vol.16, pp.1225-1233, 1989.

M. Dalaka, Immunotherapy of myositis: issues, concerns and future prospects, Nature Reviews Rheumatology, vol.2, issue.3, pp.129-166, 2010.
DOI : 10.1038/nrrheum.2010.2

M. Dalakas, Polymyositis, Dermatomyositis, and Inclusion-Body Myositis, New England Journal of Medicine, vol.325, issue.21, pp.1487-98, 1991.
DOI : 10.1056/NEJM199111213252107

M. Dalakas, Sporadic inclusion body myositis-diagnosis, pathogenesis and therapeutic strategie

M. Dalakas and R. Hohlfeld, Polymyositis and dermatomyositis. The Lancet, pp.971-981, 2003.

M. Dalakas, Immunotherapy of myositis: issues, concerns and future prospects, Nature Reviews Rheumatology, vol.2, issue.3, pp.129-166, 2010.
DOI : 10.1038/nrrheum.2010.2

M. Dalakas, I. I. Dambrosia, J. Soueidan, S. Stein, D. Otero et al., A Controlled Trial of High-Dose Intravenous Immune Globulin Infusions as Treatment for Dermatomyositis, New England Journal of Medicine, vol.329, issue.27
DOI : 10.1056/NEJM199312303292704

M. Danieli, L. Pettinari, R. Moretti, F. Logullo, and A. Gabrielli, Subcutaneous immunoglobulin in polymyositis and dermatomyositis: A novel application, Autoimmunity Reviews, vol.10, issue.3, pp.144-153, 2011.
DOI : 10.1016/j.autrev.2010.09.004

K. Danko, A. Pony, T. Constantin, G. Borgulya, and G. Szegedi, Long-Term Survival of Patients With Idiopathic Inflammatory Myopathies According to Clinical Features, Medicine, vol.83, issue.1, pp.35-42, 2004.
DOI : 10.1097/01.md.0000109755.65914.5e

D. Bleecker, J. , D. Paepe, B. Vanwalleghem, I. Schroder et al., Differential expression of chemokines in inflammatory myopathies, Neurology, vol.58, issue.12, pp.1779-85, 2002.
DOI : 10.1212/WNL.58.12.1779

D. Bleecker, J. Engel, and A. , Immunocytochemical study of CD45 T cell isoforms in inflammatory myopathies, Am J Pathol, vol.146, pp.1178-87, 1995.

E. Dion, P. Chérin, and C. Payan, Magnetic resonance imaging criteria for distinguishing between inclusion body myositis and polymyositis, J Rheumatol, vol.29, pp.1897-1906, 2002.

I. Elovaara, A. Apostolski, . Van-doornp, N. Gilhus, A. Hietaharju et al., EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases, European Journal of Neurology, vol.250, issue.Suppl. 1, pp.893-908, 2008.
DOI : 10.1111/j.1468-1331.2008.02246.x

A. Emslie-smith and A. Engel, Microvascular changes in early and advanced dermatomyositis: A quantitative study, Annals of Neurology, vol.23, issue.4, pp.343-56, 1990.
DOI : 10.1002/ana.410270402

A. Engel and K. Arahata, Mononuclear cells in myopathies: Quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies, Human Pathology, vol.17, issue.7, pp.704-721, 1986.
DOI : 10.1016/S0046-8177(86)80180-0

R. Euwer and R. Sonthermer, Amyopathic dermatomyositis (dermatomyositis sin?? myositis), Journal of the American Academy of Dermatology, vol.24, issue.6
DOI : 10.1016/0190-9622(91)70153-S

F. Frikha, A. Rigolet, A. Behin, B. Fautrel, S. Herson et al., Efficacy of rituximab in refractory and relapsing myositis with anti-JO1 antibodies: a report of two cases, Rheumatology, vol.48, issue.9, pp.1166-1174, 2009.
DOI : 10.1093/rheumatology/kep147

V. Gallais, B. Crickx, and S. Belaich, Facteurs de pronostic et signes prédictifs de cancer au cours de la dermatomyosite de l'adulte, Ann Dermatol Vénéréol, vol.123, pp.722-726, 1996.

A. Ghirardello, M. Rampudda, L. Ekholm, N. Bassi, E. Tarricone et al., Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay, Rheumatology, vol.49, issue.12
DOI : 10.1093/rheumatology/keq281

A. Ghirardello, S. Zampieri, and L. Iaccarino, Anti-Mi-2 antibodies, Autoimmunity, vol.5, issue.1, pp.79-83, 2005.
DOI : 10.1080/08916930400022681

N. Goebels, D. Michaelis, and M. Engelhardt, Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis., Journal of Clinical Investigation, vol.97, issue.12, pp.2905-2910, 1996.
DOI : 10.1172/JCI118749

S. Greenberg, J. Pinkus, and G. Pinkus, Interferon-??/??-mediated innate immune mechanisms in dermatomyositis, Annals of Neurology, vol.24, issue.5, pp.664-678, 2005.
DOI : 10.1002/ana.20464

R. Griggs, V. Askanas, and S. Dimauro, Inclusion body myositis and myopathies, Annals of Neurology, vol.94, issue.5, pp.705-713, 1995.
DOI : 10.1002/ana.410380504

. Griggs, . Rc, V. Askanas, S. Dimauro, A. Engel et al., Inclusion body myositis and myopathies, Annals of Neurology, vol.94, issue.5, pp.705-718, 1995.
DOI : 10.1002/ana.410380504

J. Groom, C. Fletcher, and S. Walters, BAFF and MyD88 signals promote a lupuslike disease independent of T cells, The Journal of Experimental Medicine, vol.19, issue.8, pp.1959-71, 2007.
DOI : 10.1126/science.1124978

P. Guerne, Myosites : données actuelles sur la classification le diagnostic et le traitement, Rev Med Suisse, vol.4, pp.718-727, 2008.

G. Hengstman, D. Bleeckerjl, E. Feist, J. Vissing, C. Denton et al., Open-label trial of anti-TNF-alpha in dermato-and polymyositis treated concomitantly with methotrextate

B. Hervier, H. Devilliers, R. Stanciu, A. Meyer, Y. Uzunhan et al., Hierarchical cluster and survival analyses of antisynthetase syndrome: Phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity, Autoimmunity Reviews, vol.12, issue.2, pp.210-217, 2012.
DOI : 10.1016/j.autrev.2012.06.006

B. Hervier, Y. Uzunhan, E. Hachulla, O. Benveniste, H. Nunes et al., Antisynthetase syndrome positive for anti-threonyl-tRNA synthetase (anti-PL7) antibodies, European Respiratory Journal, vol.37, issue.3, pp.714-721, 2011.
DOI : 10.1183/09031936.00104310

URL : https://hal.archives-ouvertes.fr/hal-00873290

C. Hill, Y. Zhang, and B. Sigurgeirsson, Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study, The Lancet, vol.357, issue.9250, pp.96-100, 2001.
DOI : 10.1016/S0140-6736(00)03540-6

R. Holfeld and A. Engel, Coculture with autologous myotubes of cytotoxic T cells isolated from muscle in inflammatory myopathies, Annals of Neurology, vol.5, issue.5, pp.498-507, 1991.
DOI : 10.1002/ana.410290509

M. Visser and R. A. Hughes, 119 th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 october, Neuromuscul Disord, vol.14, pp.337-345, 2003.

F. Iannone, C. Scioscia, P. Falappone, M. Covelli, and G. Lapadula, Use of etanercept in the treatment of dermatomyositis : a case series, J Rheumtaol, vol.33, pp.1802-1806, 2006.

M. Joffe, L. Love, R. Leff, D. Fraser, I. Targoff et al., Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy, The American Journal of Medicine, vol.94, issue.4, pp.379-87, 1993.
DOI : 10.1016/0002-9343(93)90148-I

K. Kaji, M. Fujimoto, M. Hasegawa, M. Kondo, Y. Saito et al., Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy, Rheumatology, vol.46, issue.1, pp.25-28, 2007.
DOI : 10.1093/rheumatology/kel161

E. Kang, R. Nakashima, T. Mimori, J. Kim, V. Lee et al., Myositis autoantibodies in Korean patients with inflammatory myositis: Anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis, BMC Musculoskeletal Disorders, vol.49, issue.1, p.223, 2010.
DOI : 10.1093/rheumatology/keq153

A. Kao, D. Lacomis, M. Luca, N. Fertig, and C. Oddis, Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy, Arthritis & Rheumatism, vol.73, issue.1, pp.209-224, 2004.
DOI : 10.1002/art.11484

A. Kimball, R. Summers, and M. Turner, Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis: Implications for diagnosis and therapy, Arthritis & Rheumatism, vol.103, issue.8, pp.1866-1873, 2000.
DOI : 10.1002/1529-0131(200008)43:8<1866::AID-ANR24>3.0.CO;2-6

J. Kissel, J. Mendell, and K. Rammohan, Microvascular Deposition of Complement Membrane Attack Complex in Dermatomyositis, New England Journal of Medicine, vol.314, issue.6, pp.329-334, 1986.
DOI : 10.1056/NEJM198602063140601

R. Klein, M. Rosenbach, E. Kim, V. Werth, and J. Dunham, Tumor Necrosis Factor Inhibitor???Associated Dermatomyositis, Archives of Dermatology, vol.146, issue.7, pp.780-784, 2010.
DOI : 10.1001/archdermatol.2010.142

M. Koenig, M. Fritzler, I. Targoff, Y. Troyanov, and J. Senecal, Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes, Arthritis Research & Therapy, vol.9, issue.4, p.78, 2007.
DOI : 10.1186/ar2276

B. Koffman, M. Rugiero, and M. Dalakas, Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis, Muscle & Nerve, vol.12, issue.1, pp.115-117, 1998.
DOI : 10.1002/(SICI)1097-4598(199801)21:1<115::AID-MUS15>3.0.CO;2-2

E. Koh, A. Seow, B. Ong, P. Ratnagopal, H. Tjia et al., Adult onset polymyositis/dermatomyositis: clinical and laboratory features and treatment response in 75 patients., Annals of the Rheumatic Diseases, vol.52, issue.12, pp.857-61, 1993.
DOI : 10.1136/ard.52.12.857

L. Laccarino, A. Ghirardello, S. Bettio, M. Zen, M. Gatto et al., The clinical features, diagnosis and classification of dermatomyositis, Journal of Autoimmunity, vol.48, pp.122-127, 2014.

S. Lakhanpal, T. Bunch, and D. Ilstrup, Polymyositis-Dermatomyositis and Malignant Lesions: Does an Association Exist?, Mayo Clinic Proceedings, vol.61, issue.8, pp.645-653, 1986.
DOI : 10.1016/S0025-6196(12)62030-8

R. Laxer, L. Stein, and R. Petty, Intravenous pulse methylprednisolone treatment of juvenile dermatomyositis, Arthritis & Rheumatism, vol.23, issue.3, pp.328-334, 1987.
DOI : 10.1002/art.1780300312

I. Lazarou and P. Guerne, Classification, Diagnosis, and Management of Idiopathic Inflammatory Myopathies, The Journal of Rheumatology, vol.40, issue.5, pp.550-64, 2013.
DOI : 10.3899/jrheum.120682

I. Lazarou and P. Guerne, Classification, Diagnosis, and Management of Idiopathic Inflammatory Myopathies, The Journal of Rheumatology, vol.40, issue.5, pp.550-564, 2013.
DOI : 10.3899/jrheum.120682

Y. Leow and C. Goh, Malignancy in adult dermatomyositis, International Journal of Dermatology, vol.36, issue.12, pp.904-907, 1997.
DOI : 10.1046/j.1365-4362.1997.00190.x

M. Levin, T. Mozaffar, M. Al-lozi, and A. Pestronk, Paraneoplastic necrotizing myopathy: Clinical and pathologic features, Neurology, vol.50, issue.3, pp.764-771, 1998.
DOI : 10.1212/WNL.50.3.764

C. Lindberg, A. Oldfors, and A. Tarkowski, Restricted use of T cell receptor V genes in endomysial infiltrates of patients with inflammatory myopathies, European Journal of Immunology, vol.24, issue.11, pp.2659-2663, 1994.
DOI : 10.1002/eji.1830241114

S. Lynn, S. Sawyers, P. Moller, O. Donnell, J. Chapman et al., Adult-onset inflammatory myopathy: North Canterbury experience 1989-2001, Internal Medicine Journal, vol.28, issue.3, pp.170-173, 2005.
DOI : 10.1111/j.1445-5994.2004.00764.x

S. Maillard, R. Jones, and C. Owens, Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis, Rheumatology, vol.43, issue.5, pp.603-608, 2004.
DOI : 10.1093/rheumatology/keh130

A. L. Mammen, Dermatomyositis and polymyositis, Annals of the New York Academy of Sciences, vol.4, issue.Pt 6, pp.134-153, 2010.
DOI : 10.1111/j.1749-6632.2009.05119.x

L. Manchul, J. A. Pritchard, and K. , The frequency of malignant neoplasms in patients with polymyositis-dermatomyositis. A controlled study, Archives of Internal Medicine, vol.145, issue.10, pp.1835-1839, 1985.
DOI : 10.1001/archinte.145.10.1835

I. Marie, E. Hachulla, P. Chérin, S. Dominique, P. Hatron et al., Interstitial lung disease in polymyositis and dermatomyositis, Arthritis Care & Research, vol.26, issue.Suppl 5, pp.614-636, 2002.
DOI : 10.1002/art.10794

I. Marie, P. Hatron, S. Dominique, P. Chérin, L. Mouthon et al., Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: A series of 107 patients, Arthritis & Rheumatism, vol.41, issue.Suppl 5
DOI : 10.1002/art.30513

I. Marie, P. Hatron, and H. Levesque, Influence of Age on Characteristics of Polymyositis and Dermatomyositis in Adults, Medicine, vol.78, issue.3, pp.139-147, 1999.
DOI : 10.1097/00005792-199905000-00001

I. Marie, S. Jossse, O. Decaux, S. Dominique, E. Diot et al., Comparaison of long-term outcome between JO-1 and antiPL7-PL-12 positive patients with antisynthetase syndrome

I. Marie, J. Menard, P. Hatron, E. Hachulla, L. Mouthon et al., Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: A series of 73 patients, Arthritis Care & Research, vol.10, issue.12, pp.1748-55, 2010.
DOI : 10.1002/acr.20325

I. Marie and L. Mouthon, Therapy of polymyositis and dermatomyositis, Autoimmunity Reviews, vol.11, issue.1, pp.6-13, 2011.
DOI : 10.1016/j.autrev.2011.06.007

I. Marie, Morbidity and Mortality in Adult Polymyositis and Dermatomyositis, Current Rheumatology Reports, vol.15, issue.3, pp.275-285, 2012.
DOI : 10.1007/s11926-012-0249-3

S. Matsubara, Y. Sawa, M. Takamori, H. Yokoyama, and H. Kida, Pulsed intravenous methylprednisolone combined with oral steroids as the initial treatment of inflammatory myopathies., Journal of Neurology, Neurosurgery & Psychiatry, vol.57, issue.8, p.1008, 1994.
DOI : 10.1136/jnnp.57.8.1008

A. Meyer, N. Meyer, M. Schaeffer, G. J. Geny, B. Sibilia et al., Incidence and prevalence of inflammatory myopathies: a systematic review, Rheumatology, vol.54, issue.1, pp.50-63, 2015.
DOI : 10.1093/rheumatology/keu289

O. Meyer, F. Cremer-legmann, T. Haim, and A. Ryckewaert, The principal antinuclear and anticytoplamic antibodies in polymyositis and dermatomyositis. Study of 42 cases, Press Med, vol.16, pp.155-163, 1987.

O. Meyer, P. Kaiser, and T. Haim, Anti-vascular endothelial cell antibodies (AECA): comparison of two assay methods and clinical applications, Rev Rhum (Engl Ed, vol.62, pp.737-747, 1995.

F. Miller, S. Leitman, M. Cronin, J. Hicks, R. Leff et al., Controlled Trial of Plasma Exchange and Leukapheresis in Polymyositis and Dermatomyositis, New England Journal of Medicine, vol.326, issue.21, pp.1380-1384, 1992.
DOI : 10.1056/NEJM199205213262102

J. Miller, Y. Walsh, S. Saminaden, B. Lecky, and J. Winer, Randomised double blind controlled trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy, J Neurol Sci, vol.199, issue.1, p.53, 2002.

C. Pisoni, M. Cuadrado, M. Khamashta, G. Hughes, D. Cruz et al., Mycophenolate mofetil treatment in resistant myositis, Rheumatology, vol.46, issue.3, pp.516-524, 2007.
DOI : 10.1093/rheumatology/kel336

A. Ponyi, . Constantint, and M. Garami, Cancer-Associated Myositis: Clinical Features and Prognostic Signs, Annals of the New York Academy of Sciences, vol.144, issue.1, pp.64-71, 2005.
DOI : 10.1196/annals.1361.047

S. Prieto and J. Grau, The geoepidemiology of autoimmune muscle disease, Autoimmunity Reviews, vol.9, issue.5, pp.330-334, 2010.
DOI : 10.1016/j.autrev.2009.11.006

A. Reed and S. Ytterberg, Genetic and environmental risk factors for idiopathic inflammatory myopathies, Rheumatic Disease Clinics of North America, vol.28, issue.4, pp.891-916, 2002.
DOI : 10.1016/S0889-857X(02)00029-7

J. Roebker, J. Case, and S. Lear, Immunoperoxidase Technique on Paraffin Sections Fails to Demonstrate Immunoglobulin Deposition in Cutaneous Lesions from Patients with Dermatomyositis, The American Journal of Dermatopathology, vol.10, issue.4, pp.297-299, 1988.
DOI : 10.1097/00000372-198808000-00003

DOI : 10.1093/brain/89.4.747

C. Rose, P. Hatron, and M. Brouillard, Signes pr??dictifs de cancers au cours de la dermatomyosite. ??tude de 29 observations, La Revue de M??decine Interne, vol.15, issue.1, pp.19-24, 1994.
DOI : 10.1016/S0248-8663(05)82125-3

S. Roux, H. Seelig, and O. Meyer, Significance of MI-2 autoantibodies in polymyositis and dermatomyositis, J Rheumatol, vol.25, pp.395-396, 1998.

A. Sallum, S. Marie, and A. Wakamatsu, Immunohistochemical analysis of adhesion molecule expression on muscle biopsy specimens from patients with juvenile dermatomyositis, J Rheumatol, vol.31, pp.801-808, 2004.

S. Sato, M. Hirakata, and M. Kuwana, Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis, Arthritis & Rheumatism, vol.40, issue.5, pp.1571-1577, 2005.
DOI : 10.1002/art.21023

E. Schiopu, K. Phiillips, P. Macdonald, L. Crofford, and E. Somers, Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine, Arthritis Research & Therapy, vol.14, issue.1, p.22, 2012.
DOI : 10.1002/art.24904

C. Schneider, R. Gold, and M. Dalakas, MHC Class l-Mediated Cytotoxicity Does Not Induce Apoptosis in Muscle Fibers nor in Inflammatory T Cells, Journal of Neuropathology and Experimental Neurology, vol.55, issue.12, pp.1205-1209, 1996.
DOI : 10.1097/00005072-199612000-00003

P. Schneider, F. Mackay, and V. Steiner, BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth, The Journal of Experimental Medicine, vol.85, issue.11, pp.1747-56, 1999.
DOI : 10.1126/science.7537388

M. Sem, O. Molberg, M. Lund, and J. Gran, Rituximab treatment of the anti-synthetase syndrome--a retrospective case series, Rheumatology, vol.48, issue.8, pp.968-71, 2009.
DOI : 10.1093/rheumatology/kep157

E. Shamim, L. Rider, and F. Miller, Update on the genetics of the idiopathic inflammatory myopathies, Current Opinion in Rheumatology, vol.12, issue.6, pp.482-491, 2000.
DOI : 10.1097/00002281-200011000-00002

A. Shimojima, T. Gono, K. Yamamoto, K. Hoshi, M. Matsuda et al., Efficacy of tacrolimus in treatment of polymyositis associated with myasthenia gravis, Clinical Rheumatology, vol.23, issue.3, pp.262-267, 2004.
DOI : 10.1007/s10067-004-0865-z

J. Sibilia, E. Chatelus, A. Meyer, J. Gottenberg, C. Sordet et al., Comment faire le diagnostic et mieux comprendre les myopathies inflammatoires??? L???utilit?? des auto-anticorps, La Presse M??dicale, vol.39, issue.10, pp.1010-1025, 2010.
DOI : 10.1016/j.lpm.2010.06.008

A. Sparsa, E. Liozon, and F. Herrmann, Routine vs Extensive Malignancy Search for Adult Dermatomyositis and Polymyositis, Archives of Dermatology, vol.138, issue.7, pp.885-890, 2002.
DOI : 10.1001/archderm.138.7.885

R. Stanciu, M. Guiguet, L. Musset, D. Touitou, C. Beigelman et al., Antisynthetase Syndrome with Anti-Jo1 Antibodies in 48 Patients: Pulmonary Involvement Predicts Disease-modifying Antirheumatic Drug Use, The Journal of Rheumatology, vol.39, issue.9, pp.1835-1844, 2012.
DOI : 10.3899/jrheum.111604

K. Stone, C. Oddis, N. Fertig, Y. Katsumata, M. Luca et al., Anti???Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy, Arthritis & Rheumatism, vol.169, issue.9, pp.3125-3156, 2007.
DOI : 10.1002/art.22865

S. Sultan, Y. Ioannou, and K. Moss, Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality, Rheumatology, vol.41, issue.1, pp.22-28, 2002.
DOI : 10.1093/rheumatology/41.1.22

J. Swigris, A. Olson, A. Fischer, D. Lynch, G. Cosgrove et al., Mycophenolate Mofetil Is Safe, Well Tolerated, and Preserves Lung Function in Patients With Connective Tissue Disease-Related Interstitial Lung Disease, Chest, vol.130, issue.1, pp.30-36, 2006.
DOI : 10.1016/S0012-3692(15)50949-5

P. Tonin, P. Lewis, S. Servidei, and S. Dimauro, Metabolic causes of myoglobinuria, Annals of Neurology, vol.38, issue.2, pp.181-186, 1990.
DOI : 10.1002/ana.410270214

W. Tormey, Serum aldolase with creatine kinase in current clinical practice, Br J Clin Prat, vol.44, pp.582-586, 1990.

C. Torres, R. Belmonte, L. Carmona, F. Gomez-reino, M. Galindo et al., Survival, mortality and causes of death in inflammatory myopathies, Autoimmunity, vol.125, issue.3, pp.205-215, 2006.
DOI : 10.1016/0049-0172(86)90014-4

S. Toumi, H. Ghnaya, A. Braham, I. Harrabi, and C. Laouani-kechrid, Les polymyosites et dermatomyosites de l'adulte. Etude multicentrique tunisienne

A. Tournadre, Prise en charge th??rapeutique des polymyosites, dermatomyosites, myosites de chevauchement et myopathies n??crosantes auto-immunes, La Revue de M??decine Interne, vol.35, issue.7, pp.466-471, 2014.
DOI : 10.1016/j.revmed.2013.09.008

Y. Troyanov, I. Targoff, and J. Tremblay, Novel Classification of Idiopathic Inflammatory Myopathies Based on Overlap Syndrome Features and Autoantibodies, Medicine, vol.84, issue.4, pp.231-249, 2005.
DOI : 10.1097/01.md.0000173991.74008.b0

. Autoantibodies, Analysis of 100 French Canadian Patients, Medicine, vol.84, pp.231-249, 2005.

K. Tymms and J. Webb, Dermatopolymyositis and other connective tissue diseases: a review of 105 cases, J Rheumatol, vol.12, pp.1140-1148, 1985.

R. Valiyil, L. Casciola-rosen, G. Hong, A. Mammen, and L. Christopher-stine, Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: A case series, Arthritis Care & Research, vol.44, issue.9, pp.1328-1362, 2010.
DOI : 10.1002/acr.20219

M. Van-der-meulen, I. Bronner, and J. Hoogendijk, Polymyositis, Neurology, vol.61, issue.3
DOI : 10.1212/WNL.61.3.316

L. Villalba, J. Hicks, E. Adams, J. Sherman, M. Gourley et al., Treatment of refractory myositis: A randomized crossover study of two new cytotoxic regimens, Arthritis & Rheumatism, vol.270, issue.3, pp.392-401, 1998.
DOI : 10.1002/1529-0131(199803)41:3<392::AID-ART3>3.0.CO;2-X

N. Wakata, T. Kurihara, and E. Saito, Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study, International Journal of Dermatology, vol.89, issue.93, pp.729-734, 2002.
DOI : 10.1001/archderm.126.5.633

E. Yunis and F. Samaha, Inclusion body myositis, Lab Invest, vol.25, pp.240-248, 1972.

D. Zantos, Y. Zhang, and D. Felson, The overall and temporal association of cancer with polymyositis and dermatomyositis, J Rheumatol, vol.21, pp.1855-1864, 1994.

M. Cles, myopathies inflammatoires; polymyosites; dermatomyosites ; myopathies nécrosantes auto-immunes ; myosites à inclusions ; classifications ; auto-anticorps